Outcomes from treating orthopedic infection with debridement and implanted antibiotic were similar whether followed by short or standard duration of systemic antibiotic.
|Articles|February 7, 2016
Beards May Hold the Answer to New Antibiotics
Author(s)Caitlyn Fitzpatrick
After swabbing 20 beards, more than 100 bacteria growths were identified.
Advertisement
With antibiotic resistance on the rise and new antibiotics far and few between, the need for novel medications is as serious as ever. But research from the University College London (UCL) may have found an unlikely answer: beards.
“What we’ve done as a human species is to basically coat the world in antibiotics by our overuse and inappropriate use. So, we’ve selected for these resistance mechanisms in the bacteria, so it’s why we’re seeing the problem that we’re seeing now,” Adam Roberts, PhD, a microbiologist from the UCL, said in a
So what do beards have to do with antibiotics? Previous research has shown that beards contained fecal bacteria. The researchers from UCL wanted to confirm if this was true, and so they conducted a study of their own. They did not find evidence of fecal bacteria in beards; however, they took the data to further evaluate different bacteria.
After swabbing 20 beards, more than 100 bacteria growths were identified.
“What we do is grid out the individual bacteria on an agar plate which has been pre-inoculated with an indicator strain. And then we see if that indicator strain can grow right up to the individual colonies from the beards or from anywhere else that we’ve got these bacteria from,” Roberts explained.
He went on to reveal, “we found, quite surprisingly, that the beard isolates were quite capable of killing the indicator strain that we have; showing that they actually produce antibiotics themselves.”
About 25% of the 20 beards proved to have antibiotic activity against the indicator strain.
The UCL team continues to dig further into antibiotic-resistant bacteria and strategies to develop new medications to fight the epidemic. Roberts says that by developing new antibiotics, it will give health care providers the opportunity to limit the use so that bacteria won’t become resistance. He’s asked the public for samples in order to gather more information.
“We’ve got other samples from all over the country; from child’s trampolines, to fridges, to cats,” Roberts continued. “We’ve now got a selection of around 50 different bacteria which can kill multiple indicator strains. These include E. coli — a multi-drug resistant E. coli from a urinary tract infection. These include also Candida albicans (yeast infections) and MRSA (Methicillin-resistant Staphylococcus aureus).”
New antibiotics could be on the way… with a little help from beards.
Advertisement
Related to this article
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Adding bismuth to amoxicillin-vonoprazan increased efficacy of the combination for H pylori, and exceeded that of clarithromycin-based triple therapy without contributing to clarithromycin resistance.
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Advertisement
Advertisement
Trending on Contagion Live
1
How The Food Safety Surveillance Infrastructure Works in the US
2
Evaluating Ebola Vaccine Against Current Bundibugyo Species
3
Ebola and the Ongoing Tale of US Failures
4
Implanted Antibiotic Reduced Systemic Regimen for Orthopedic Infection
5